• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Weekly, May 09, 2016

The CenterWatch Weekly, May 09, 2016

May 9, 2016
CenterWatch Staff

Surprise Quintiles-IMS Health merger may signal rising value of data assets

In a move that sent shockwaves through the life sciences industry last week, Quintiles Transnational Holdings and IMS Health Holdings announced an all-stock merger of equals—a transaction that ranks as the largest CRO merger in history. The com­bined equity market capitalization of the two companies is more than $17.6 billion, and the enterprise value is more than $23 billion. “The surprising thing is that this is an enormous deal for this space,” said Tim Evans, senior analyst at Wells Fargo Securities Equity Research. “The strategic significance remains to be seen, but the big picture here is that data is going to matter a lot more in terms of how clinical trials are conducted.”

 

McConnell Centers for Innovative Medicine is the new model for patient engagement

 The McConnell Centre for Innovative Medicine (CIM), a standalone research institution just a skywalk away from the Research Institute at McGill University Health Centre (RI-MUHC), has opened. The new RI-MUHC super hospital and research center is designed to connect physicians, nurses and researchers. By work­ing together, they can develop and evaluate complex medical problems and make use of industry innovation, including diagnostic tools and therapies.

 

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing